Helicobacter pylori(H.pylori)infection is widely prevalent worldwide.H.pylori infection has been reported to be a risk factor for the development of insulin resistance,nonalco-holic fatty liver disease(NAFLD),nonalcoh...Helicobacter pylori(H.pylori)infection is widely prevalent worldwide.H.pylori infection has been reported to be a risk factor for the development of insulin resistance,nonalco-holic fatty liver disease(NAFLD),nonalcoholic steatohepatitis(NASH),liver fibrosis,and cirrhosis.Because treatment for NAFLD,other than weight loss is limited,the treatment for H.pylori infection is well established.It is important to determine whether screening and treatment for H.pylori infection should be considered in patients with no gastrointestinal symptoms.The aim of this mini-review is to evaluate the association be-tween H.pylori infection and NAFLD including epidemiology,pathogenesis,and the evidence for H.pylori infection as a modifiable risk factor for preventing or treating NAFLD.展开更多
AIM: To investigate the potential association of circulating zonulin with the stage of liver disease in obese children with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD).
Nonalcoholic steatohepatitis(NASH)has emerged as the leading cause of chronic liver disease worldwide and is rapidly increasing in prevalence due to the obesity epidemic.There are currently no Food and Drug Administra...Nonalcoholic steatohepatitis(NASH)has emerged as the leading cause of chronic liver disease worldwide and is rapidly increasing in prevalence due to the obesity epidemic.There are currently no Food and Drug Administration(FDA)approved drugs to treat NASH,and therefore a critical need exists for novel therapies that can halt or reverse the progression to hepatic fibrosis,cirrhosis,and hepatocellular carcinoma.Clinical trials to date using single drugs to treat NASH have shown disappointing efficacy.Combination therapies to attack different targets underlying disease pathogenesis of NASH are being explored as a strategy currently.Novel RNA therapies are also being developed to target previously“undruggable”targets and are close to the maturity necessary to be viable therapeutic approaches for the treatment of NASH and fibrosis.Identifying circulating biomarkers of fibrosis could serve as a valuable,non-invasive diagnostic tool to guide clinical practice.Despite progress in translational and clinical research,one of the major reasons for the absence of effective therapeutics is our incomplete understanding of the pathophysiology that underlies the progression from steatosis to NASH and its most deadly consequence-fibrosis.Multi-omics platforms will help to drive effective precision medicine development in NASH and hepatology.展开更多
文摘Helicobacter pylori(H.pylori)infection is widely prevalent worldwide.H.pylori infection has been reported to be a risk factor for the development of insulin resistance,nonalco-holic fatty liver disease(NAFLD),nonalcoholic steatohepatitis(NASH),liver fibrosis,and cirrhosis.Because treatment for NAFLD,other than weight loss is limited,the treatment for H.pylori infection is well established.It is important to determine whether screening and treatment for H.pylori infection should be considered in patients with no gastrointestinal symptoms.The aim of this mini-review is to evaluate the association be-tween H.pylori infection and NAFLD including epidemiology,pathogenesis,and the evidence for H.pylori infection as a modifiable risk factor for preventing or treating NAFLD.
文摘AIM: To investigate the potential association of circulating zonulin with the stage of liver disease in obese children with biopsy-confirmed nonalcoholic fatty liver disease (NAFLD).
文摘Nonalcoholic steatohepatitis(NASH)has emerged as the leading cause of chronic liver disease worldwide and is rapidly increasing in prevalence due to the obesity epidemic.There are currently no Food and Drug Administration(FDA)approved drugs to treat NASH,and therefore a critical need exists for novel therapies that can halt or reverse the progression to hepatic fibrosis,cirrhosis,and hepatocellular carcinoma.Clinical trials to date using single drugs to treat NASH have shown disappointing efficacy.Combination therapies to attack different targets underlying disease pathogenesis of NASH are being explored as a strategy currently.Novel RNA therapies are also being developed to target previously“undruggable”targets and are close to the maturity necessary to be viable therapeutic approaches for the treatment of NASH and fibrosis.Identifying circulating biomarkers of fibrosis could serve as a valuable,non-invasive diagnostic tool to guide clinical practice.Despite progress in translational and clinical research,one of the major reasons for the absence of effective therapeutics is our incomplete understanding of the pathophysiology that underlies the progression from steatosis to NASH and its most deadly consequence-fibrosis.Multi-omics platforms will help to drive effective precision medicine development in NASH and hepatology.
